Cargando…

Identification of Lethal Inhibitors and Inhibitor Combinations for Mono-Driver versus Multi-Driver Triple-Negative Breast Cancer Cells

SIMPLE SUMMARY: Triple-negative breast cancers lack estrogen and progesterone receptors and HER2. They lack effective targeted therapies and tend to be more aggressive, with the worst five-year overall survival and a higher rate of recurrence. This study investigates the oncogenic signaling mechanis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ku, Geng Chia, Chapdelaine, Abygail G., Ayrapetov, Marina K., Sun, Gongqin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9407008/ https://www.ncbi.nlm.nih.gov/pubmed/36011019 http://dx.doi.org/10.3390/cancers14164027

Ejemplares similares

Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer
por: Chapdelaine, Abygail G., et al.
Publicado: (2023)

Dissection of the catalytic and regulatory structure-function relationships of Csk protein tyrosine kinase
por: Sun, Gongqin, et al.
Publicado: (2023)

Characterization of the interactions between the active site of a protein tyrosine kinase and a divalent metal activator
por: Lin, Xiaofeng, et al.
Publicado: (2005)

Identification of drivers of mycobacterial resistance to peptidoglycan synthesis inhibitors
por: Olivença, Francisco, et al.
Publicado: (2022)

Drug Sensitivity Screening and Targeted Pathway Analysis Reveal a Multi-Driver Proliferative Mechanism and Suggest a Strategy of Combination Targeted Therapy for Colorectal Cancer Cells
por: Shen, Jinyan, et al.
Publicado: (2019)

Biphasic Mathematical Model of Cell–Drug Interaction That Separates Target-Specific and Off-Target Inhibition and Suggests Potent Targeted Drug Combinations for Multi-Driver Colorectal Cancer Cells
por: Shen, Jinyan, et al.
Publicado: (2020)

Negativity Bias in Dangerous Drivers
por: Chai, Jing, et al.
Publicado: (2016)

Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer
por: Zurlo, Giada, et al.
Publicado: (2019)

DriverDBv3: a multi-omics database for cancer driver gene research
por: Liu, Shu-Hsuan, et al.
Publicado: (2020)

Drivers of coffee liking: Effect of physicochemical characteristics and aromatic profile on consumers’ acceptability of mono‐origin and mono‐variety coffees
por: Condelli, Nicola, et al.
Publicado: (2022)

Engineering mono- and multi-valent inhibitors on a modular scaffold
por: Diamante, Aurora, et al.
Publicado: (2020)

CRIF1-CDK2 Interface Inhibitors Enhance Taxol Inhibition of the Lethal Triple-Negative Breast Cancer
por: Sang, Xiaoye, et al.
Publicado: (2022)

Biomarkers of related driver genes predict anti-tumor efficacy of immune checkpoint inhibitors
por: Jiang, Shuai, et al.
Publicado: (2022)

Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells
por: Ha, Kyungsoo, et al.
Publicado: (2014)

DriverGenePathway: Identifying driver genes and driver pathways in cancer based on MutSigCV and statistical methods
por: Xu, Xiaolu, et al.
Publicado: (2023)

Code for the new MultiBus CAMAC driver compatible with the old Multibus CAMAC driver
por: Richardson, T J
Publicado: (1994)

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
por: Turner, Nicholas, et al.
Publicado: (2010)

A network approach reveals driver genes associated with survival of patients with triple-negative breast cancer
por: Dill, Courtney D., et al.
Publicado: (2021)

Malignancy of Cancers and Synthetic Lethal Interactions Associated With Mutations of Cancer Driver Genes
por: Wang, Xiaosheng, et al.
Publicado: (2016)

Efficacy and Safety Analysis of Immune Checkpoint Inhibitors plus Angiogenesis Inhibitors for the Treatment of Advanced Driver-negative NSCLC in Elderly Patients: A Retrospective Study
por: Zhang, Jian, et al.
Publicado: (2023)

Developing drivers with the Windows driver foundation
por: Orwick, Penny, et al.
Publicado: (2007)

DriverDB: an exome sequencing database for cancer driver gene identification
por: Cheng, Wei-Chung, et al.
Publicado: (2014)

AlloDriver: a method for the identification and analysis of cancer driver targets
por: Song, Kun, et al.
Publicado: (2019)

Soluble and Cell–Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma
por: Farrell, Mariah L., et al.
Publicado: (2018)

Drivers and Inhibitors in the Acceptance of Meat Alternatives: The Case of Plant and Insect-Based Proteins
por: de Koning, Wim, et al.
Publicado: (2020)

Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
por: Miura, Yosuke, et al.
Publicado: (2019)

Exploring the Chemical Space of Urease Inhibitors to Extract Meaningful Trends and Drivers of Activity
por: Aniceto, Natália, et al.
Publicado: (2022)

Unexplained abdominal pain as a driver for inappropriate therapeutics: an audit on the use of intravenous proton pump inhibitors
por: Lai, Pauline Siew Mei, et al.
Publicado: (2014)

Cultural and Contextual Drivers of Triple Burden of Malnutrition among Children in India
por: Singh, Shri Kant, et al.
Publicado: (2023)

DriverDBv2: a database for human cancer driver gene research
por: Chung, I-Fang, et al.
Publicado: (2016)

Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC
por: Huang, Yiyi, et al.
Publicado: (2023)

Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer
por: Cuenca-López, María Dolores, et al.
Publicado: (2015)

Antibodies Are Major Drivers of Protection against Lethal Aerosol Infection with Highly Pathogenic Burkholderia spp.
por: Hogan, Robert J., et al.
Publicado: (2019)

Role of BET Inhibitors in Triple Negative Breast Cancers
por: Khandekar, Durga, et al.
Publicado: (2020)

HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer
por: Maccallini, Cristina, et al.
Publicado: (2022)

Drivers with and without Obesity Respond Differently to a Multi-Component Health Intervention in Heavy Goods Vehicle Drivers
por: Ruettger, Katharina, et al.
Publicado: (2022)

Generation and Analysis of Serine Protease Inhibitor Kazal Type 3-Cre Driver Mice
por: Sakata, Kazuya, et al.
Publicado: (2014)

Small molecule inhibitors reveal PTK6 kinase is not an oncogenic driver in breast cancers
por: Qiu, Luping, et al.
Publicado: (2018)

Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitors
por: Crosby, Erika J., et al.
Publicado: (2021)

MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer
por: Bhin, Jinhyuk, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2ji596qnml8u2joeb533mp3a8r